RecruitingNCT04085029
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Sponsor
Duke University
Enrollment
300 participants
Start Date
Sep 26, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥ 18 years of age
- Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
- Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
- Patient must sign study-specific informed consent
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04085029
Related Trials
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT0478774420 locations
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT063461975 locations
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT0526762618 locations
Comparison of Whole Body DWI to FDG PET
NCT066308451 location
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
NCT071440851 location